comprehensive -WSS

comprehensive

author：focus 2025-10-02 00:18:15 - browse：42

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Congenital heart disease patients face new threat of heart failure

entertainment

explore

WSS

Why are Kaiser Permanente staff considering a strike?

STAT Virtual Event: Putting AI to the Test

Thermo Fisher plant for manufacturing gene therapies to expand

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

AI models in health care face new federal disclosure requirements

Senators: Long

hotspot

comprehensive

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD podcast: possible new ALS drug, artificial wombs

Novavax promises a turnaround & Lilly roils the obesity market

Changes to biosimilar regulatory framework must prioritize patients

BioMarin wins approval for gene therapy to treat hemophilia A

Spinal cord stimulation reduces pain in amputees, study finds

Walensky prepares to leave CDC — and Congress — behind

Changes to biosimilar regulatory framework must prioritize patients

Anesthesiologist group: stop taking Ozempic before surgery

FDA approves world's first CRISPR

hotspot

CMS should re

How Vertex's cystic fibrosis drug is changing patients' lives

Pregnancy discrimination could be enabled by AI

Biotech lab space demand falls sharply

CMS should re

Pfizer plans to depart BIO

entertainment

entertainment

explore

hotspot